126 related articles for article (PubMed ID: 16019499)
1. Alemtuzumab-induced syndrome of inappropriate anti-diuretic hormone.
Kunz JS; Bannerji R
Leuk Lymphoma; 2005 Apr; 46(4):635-7. PubMed ID: 16019499
[No Abstract] [Full Text] [Related]
2. Alemtuzumab.
Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
[No Abstract] [Full Text] [Related]
3. Alemtuzumab.
Williamson TS
Clin J Oncol Nurs; 2001; 5(6):287-8. PubMed ID: 11899633
[No Abstract] [Full Text] [Related]
4. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
Thompson CA
Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
[No Abstract] [Full Text] [Related]
5. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Cavalli-Björkman N; Osby E; Lundin J; Kalin M; Osterborg A; Gruber A
Med Oncol; 2002; 19(4):277-80. PubMed ID: 12512923
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.
Pettitt AR; Matutes E; Oscier D
Leukemia; 2006 Aug; 20(8):1441-5. PubMed ID: 16738694
[No Abstract] [Full Text] [Related]
7. Taking the measure of alemtuzumab.
Gilleece MH
Leuk Res; 2004 Dec; 28(12):1253-4. PubMed ID: 15475064
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia.
Laurenti L; Tarnani M; Efremov DG; Chiusolo P; De Padua L; Sica S; Leone G
Leukemia; 2007 Aug; 21(8):1819-21; author reply 1821. PubMed ID: 17443222
[No Abstract] [Full Text] [Related]
9. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
[TBL] [Abstract][Full Text] [Related]
10. Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way.
Tam CS
Leuk Lymphoma; 2009 Oct; 50(10):1557-8. PubMed ID: 19757304
[No Abstract] [Full Text] [Related]
11. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
O'Brien SM; Keating MJ; Mocarski ES
Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
[TBL] [Abstract][Full Text] [Related]
12. Coronary ischemia related to alemtuzumab therapy.
Basquiera AL; Berretta AR; García JJ; Palazzo ED
Ann Oncol; 2004 Mar; 15(3):539-40. PubMed ID: 14998865
[No Abstract] [Full Text] [Related]
13. Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia.
Ammatuna E; Sarlo C; Ottaviani L; Quaresima M; Buccisano F; Campagna S; Del Principe MI; De Angelis G; Anemona L; Gumenyuk S; Amadori S; Venditti A
Leuk Lymphoma; 2009 May; 50(5):857-8. PubMed ID: 19330655
[No Abstract] [Full Text] [Related]
14. Alemtuzumab until minimal residual disease for chronic lymphocytic leukemia: Is it a new standard?
Goodman M
J Clin Oncol; 2005 Oct; 23(28):7240-1; author reply 7241-2. PubMed ID: 16192616
[No Abstract] [Full Text] [Related]
15. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
Demko S; Summers J; Keegan P; Pazdur R
Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062
[TBL] [Abstract][Full Text] [Related]
16. A fatal case of alemtuzumab-associated interstitial pneumonitis.
Creelan B; Ferber A
Am J Ther; 2008; 15(1):82-4. PubMed ID: 18223357
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
18. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC
Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611
[TBL] [Abstract][Full Text] [Related]
19. The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia.
Tarnani M; D'Arena G; Efremov DG; Marietti S; S S; Leone G; Laurenti L
Leukemia; 2010 Apr; 24(4):890-1. PubMed ID: 20090782
[No Abstract] [Full Text] [Related]
20. Alemtuzumab for treatment of lymphoproliferative disorders.
Haematologica; 2004 Dec; 89(12):1419. PubMed ID: 15590389
[No Abstract] [Full Text] [Related]
[Next] [New Search]
